Xconomy

JULY 22, 2016

—Celgene (NASDAQ: CELG ), of Summit, NJ, inked its latest immuno-oncology deal, forming a wide-ranging alliance with Cambridge-based Jounce Therapeutics to develop a group of cancer drugs. Also in Cambridge, Oncorus debuted with a $57 million round and a plan to develop next-gen oncolytic viruses, a type of cancer immunotherapy tool.

Startup 40

Startup San Diego News Thousand Oaks 40

Xconomy

AUGUST 5, 2016

Instead, Holmes promoted a new system, MiniLab , in development. Adicet raised $51 million earlier this year… Amgen (NASDAQ: AMGN ) of Thousand Oaks, CA, is paying $40 million immediately for rights to ADXS-NEO , a preclinical cancer treatment from Princeton, NJ-based Advaxis (NASDAQ: ADXS ).

News 40

News Thousand Oaks Pricing Report 40

Xconomy

JUNE 10, 2016

—More developments arrived this week in the Sarepta Therapeutics (NASDAQ: SRPT ) saga. —On the positive side, Thousand Oaks, CA-based Amgen (NASDAQ: AMGN ) released an overview of Phase 2 data that showed its migraine prevention drug, erenumab, is keeping pace with rival drugs in a heated race to market.

Incubator 67

Incubator Thousand Oaks Screening Pricing 67

Xconomy

SEPTEMBER 30, 2016

Who will break free of the pack of companies developing drugs meant to prevent migraines? —Amgen (NASDAQ: AMGN ), of Thousand Oaks, CA, and partner Novartis released positive results from the first Phase 3 trial of erenumab , one of a group of drugs being developed to prevent migraines , not just lessen their impact when they happen.

Avalon 40

Avalon Thousand Oaks Study Startup 40

Xconomy

AUGUST 26, 2016

—Amgen (NASDAQ: AMGN ) of Thousand Oaks, CA, said that the FDA rejected its drug etelcalcetide (Parasbiv) , a treatment for patients with an excess of damaging hormone release because of chronic kidney disease. Morgan party. The firm has since pledged to help close the gender gap among biotech leadership.

Pricing 40

Pricing Thousand Oaks Startup Research 40